[Neurostimulation of the supraorbital nerve with the Cefaly device - a new method for the treatment of migraine].
Treatment of migraine mainly includes pharmacological approaches aimed at breaking migraine attacks and preventive treatment to reduce their frequency. Despite the wide range of pharmacological agents, frequent side effects and pharmacotherapy resistance in patients with migraine determine the urgency of finding new alternative treatment strategies. The introduction of new non-invasive methods for percutaneous stimulation has fundamentally expanded the therapeutic opportunities for many patients with migraine, irrespective of the severity of the disease and responsiveness to pharmacotherapy. Stimulation of the supraorbital nerve with the percutaneous Cefaly device ('Cefaly Technology sprl', Seraing, Belgium) in clinical randomized, controlled studies has demonstrated efficacy in significantly reducing both the frequency of migraine attacks and the total number of days with headache. Cefaly is the first FDA approved migraine prevention medical device.